EX-99.1 2 veco-20250212xex99d1.htm EX-99.1

EXHIBIT 99.1

Graphic

VEECO REPORTS FOURTH QUARTER AND FISCAL YEAR 2024 FINANCIAL RESULTS

Fourth Quarter 2024 Highlights:

Revenue of $182.1 million, compared with $173.9 million in the same period last year
GAAP net income of $15.0 million, or $0.26 per diluted share, compared with $21.6 million, or $0.37 per diluted share in the same period last year
Non-GAAP net income of $24.2 million, or $0.41 per diluted share, compared with $29.8 million, or $0.51 per diluted share in the same period last year

Fiscal Year 2024 Highlights:

Revenue of $717.3 million, compared with $666.4 million in the same period last year
GAAP net income of $73.7 million, or $1.23 per diluted share, compared with GAAP net loss of $30.4 million or $0.56 loss per diluted share in the same period last year
Non-GAAP net income of $104.3 million, or $1.74 per diluted share, compared with $98.3 million, or $1.69 per diluted share in the same period last year

Plainview, N.Y., February 12, 2025 -- Veeco Instruments Inc. (Nasdaq: VECO) today announced financial results for its fourth quarter and fiscal year ended December 31, 2024. Results are reported in accordance with U.S. generally accepted accounting principles (“GAAP”) and are also reported adjusting for certain items (“Non-GAAP”). A reconciliation between GAAP and Non-GAAP operating results is provided at the end of this press release.  

U.S. Dollars in millions, except per share data

4th Quarter

Full Year

GAAP Results

 

Q4 '24

Q4 '23

2024

   

2023

Revenue

$

182.1

$

173.9

$

717.3

$

666.4

Net income (loss)

$

15.0

$

21.6

$

73.7

$

(30.4)

Diluted earnings (loss) per share

$

0.26

$

0.37

$

1.23

$

(0.56)

4th Quarter

Full Year

Non-GAAP Results

 

Q4 '24

Q4 '23

2024

2023

Operating income

$

27.4

$

32.1

$

116.1

$

109.6

Net income

$

24.2

$

29.8

$

104.3

$

98.3

Diluted earnings per share

$

0.41

$

0.51

$

1.74

$

1.69

“Veeco had a successful year in 2024, highlighted by our Semiconductor business outperforming WFE growth for the 4th consecutive year,” commented Bill Miller, Ph.D., Veeco’s Chief Executive Officer. “We achieved several strategic milestones, grew the top-line and delivered solid profitability, all while continuing to allocate capital toward our largest growth opportunities. Looking ahead, our solutions in Laser Annealing, Ion Beam Deposition, and Advanced Packaging are well-positioned to take advantage of growth in leading edge investment in the coming years.”

1


Guidance and Outlook

The following guidance is provided for Veeco’s first quarter 2025:

Revenue is expected in the range of $155 million to $175 million
GAAP diluted earnings per share are expected in the range of $0.11 to $0.22
Non-GAAP diluted earnings per share are expected in the range of $0.26 to $0.36

Conference Call Information

A conference call reviewing these results has been scheduled for today, February 12, 2025 starting at 5:00pm ET. To join the call, dial 1-877-407-8029 (toll-free) or 1-201-689-8029. Participants may also access a live webcast of the call by visiting the investor relations section of Veeco's website at ir.veeco.com. A replay of the webcast will be made available on the Veeco website that evening. We will post an accompanying slide presentation to our website prior to the beginning of the call.

About Veeco

Veeco (NASDAQ: VECO) is an innovative manufacturer of semiconductor process equipment. Our laser annealing, ion beam, chemical vapor deposition (CVD), metal organic chemical vapor deposition (MOCVD), single wafer etch & clean and lithography technologies play an integral role in the fabrication and packaging of advanced semiconductor devices. With equipment designed to optimize performance, yield and cost of ownership, Veeco holds leading technology positions in the markets we serve. To learn more about Veeco’s systems and service offerings, visit www.veeco.com.

Forward-looking Statements

This press release contains “forward-looking statements”, within the meaning of the safe harbor provisions of the U.S. Private Securities Litigation Reform Act of 1995, as amended, that are based on management’s expectations, estimates, projections and assumptions. Words such as “expects,” “anticipates,” “plans,” “believes,” “scheduled,” “estimates” and variations of these words and similar expressions are intended to identify forward-looking statements. Forward-looking statements include, but are not limited to, those regarding anticipated growth and trends in our businesses and markets, industry outlooks and demand drivers, our investment and growth strategies, our development of new products and technologies, our business outlook for current and future periods, our ongoing transformation initiative and the effects thereof on our operations and financial results; and other statements that are not historical facts. These statements and their underlying assumptions are subject to risks and uncertainties and are not guarantees of future performance. Factors that could cause actual results to differ materially from those expressed or implied by such statements include, without limitation: the level of demand for our products; global economic and industry conditions; global trade issues, including the ongoing trade disputes between the U.S. and China, and changes in trade and export license policies; our dependency on third-party suppliers and outsourcing partners; the timing of customer orders; our ability to develop, deliver and support new products and technologies; our ability to expand our current markets, increase market share and develop new markets; the concentrated nature of our customer base; our ability to obtain and protect intellectual property rights in key technologies; the effects of regional or global health epidemics; our ability to achieve the objectives of operational and strategic initiatives and attract, motivate and retain key employees; the variability of results among products and end-markets, and our ability to accurately forecast future results, market conditions, and customer requirements; the impact of our indebtedness, including our convertible senior notes and our capped call transactions; and other risks and uncertainties described in our SEC filings on Forms 10-K, 10-Q and 8-K, and from time-to-time in our other SEC reports. All forward-looking statements speak only to management’s expectations, estimates, projections and assumptions as of the date of this press release or, in the case of any document referenced herein or incorporated by reference, the date of that document. The Company does not undertake any obligation to update or publicly revise any forward-looking statements to reflect events, circumstances or changes in expectations after the date of this press release.

-financial tables attached-

Veeco Contacts:

Investors:Anthony Pappone (516) 500-8798[email protected]

Media:Brenden Wright (410) 984-2610[email protected]

2


Veeco Instruments Inc. and Subsidiaries
Condensed Consolidated Statements of Operations

(in thousands, except per share amounts)
(unaudited)

Three months ended December 31,

Year ended December 31,

 

    

2024

    

2023

    

2024

    

2023

 

Net sales

 

$

182,131

 

$

173,924

 

$

717,301

 

$

666,435

Cost of sales

 

108,146

 

95,269

 

413,296

 

381,376

Gross profit

 

73,985

 

78,655

 

304,005

 

285,059

Operating expenses, net:

Research and development

 

30,953

 

29,091

 

124,507

 

112,853

Selling, general, and administrative

 

25,077

 

23,493

 

99,663

 

92,756

Amortization of intangible assets

 

1,580

 

2,123

 

6,983

 

8,481

Asset impairment

 

28,131

 

 

28,131

 

Other operating expense (income), net

 

(15,635)

 

(235)

 

(22,260)

 

1,029

Total operating expenses, net

 

70,106

 

54,472

 

237,024

 

215,119

Operating income

 

3,879

 

24,183

 

66,981

 

69,940

Interest income (expense), net

 

476

 

 

1,853

 

(1,187)

Other income (expense), net

(97,091)

Income (loss) before income taxes

 

4,355

 

24,183

 

68,834

 

(28,338)

Income tax expense (benefit)

 

(10,610)

 

2,546

 

(4,880)

 

2,030

Net income (loss)

 

$

14,965

 

$

21,637

 

$

73,714

 

$

(30,368)

Income (loss) per common share:

Basic

 

$

0.26

 

$

0.39

 

$

1.31

 

$

(0.56)

Diluted

 

$

0.26

 

$

0.37

 

$

1.23

 

$

(0.56)

Weighted average number of shares:

Basic

 

56,536

 

55,537

 

56,426

 

53,769

Diluted

 

60,499

 

59,821

 

61,596

 

53,769

3


Veeco Instruments Inc. and Subsidiaries
Condensed Consolidated Balance Sheets

(in thousands)

December 31,

December 31,

    

2024

    

2023

(unaudited)

Assets

Current assets:

Cash and cash equivalents

$

145,595

$

158,781

Restricted cash

 

224

 

339

Short-term investments

 

198,719

 

146,664

Accounts receivable, net

 

96,834

 

103,018

Contract assets

 

37,109

 

24,370

Inventories

 

246,735

 

237,635

Prepaid expenses and other current assets

 

39,316

 

35,471

Total current assets

 

764,532

 

706,278

Property, plant and equipment, net

 

113,789

 

118,459

Operating lease right-of-use assets

26,503

 

24,377

Intangible assets, net

 

8,832

 

43,945

Goodwill

 

214,964

 

214,964

Deferred income taxes

 

120,191

 

117,901

Other assets

 

2,766

 

3,117

Total assets

$

1,251,577

$

1,229,041

Liabilities and stockholders’ equity

Current liabilities:

Accounts payable

$

43,519

$

42,383

Accrued expenses and other current liabilities

 

55,195

 

57,624

Contract liabilities

 

64,986

 

118,026

Income taxes payable

 

2,086

 

Current portion of long-term debt

26,496

Total current liabilities

 

192,282

 

218,033

Deferred income taxes

 

689

 

6,552

Long-term debt

 

249,702

 

274,941

Long-term operating lease liabilities

34,318

 

31,529

Other liabilities

 

3,816

 

25,544

Total liabilities

 

480,807

 

556,599

Total stockholders’ equity

 

770,770

 

672,442

Total liabilities and stockholders’ equity

$

1,251,577

$

1,229,041

Note on Reconciliation Tables

The below tables include financial measures adjusted for the impact of certain items; these financial measures are therefore not calculated in accordance with U.S. generally accepted accounting principles (“GAAP”). These Non-GAAP financial measures exclude items such as: share-based compensation expense; charges relating to restructuring initiatives; non-cash asset impairments; certain other non-operating gains and losses; and acquisition-related items such as transaction costs, non-cash amortization of acquired intangible assets, and certain integration costs.

These Non-GAAP financial measures may be different from Non-GAAP financial measures used by other companies. Non-GAAP financial measures should not be considered a substitute for, or superior to, measures of financial performance prepared in accordance with GAAP. By excluding these items, Non-GAAP financial measures are intended to facilitate meaningful comparisons to historical operating results, competitors’ operating results, and estimates made by securities analysts. Management is evaluated on key performance metrics including Non-GAAP Operating income (loss), which is used to determine management incentive compensation as well as to forecast future periods. These Non-GAAP financial measures may be useful to investors in allowing for greater transparency of supplemental information used by management in its financial and operational decision-making. In addition, similar Non-GAAP financial measures have historically been reported to investors; the inclusion of comparable numbers provides consistency in financial reporting. Investors are encouraged to review the reconciliation of the Non-GAAP financial measures used in this news release to their most directly comparable GAAP financial measures.

4


Reconciliation of GAAP to Non-GAAP Financial Data (Q4 2024)

(in thousands)
(unaudited)

Non-GAAP Adjustments

 

Share-Based

 

Three months ended December 31, 2024

    

GAAP

    

Compensation

    

Amortization

    

Other

    

Non-GAAP

 

Net sales

$

182,131

$

182,131

 

Gross profit

 

73,985

 

1,523

 

 

75,508

Gross margin

 

40.6

%

 

41.5

%

Operating expenses

 

70,106

 

(7,582)

(1,580)

(12,876)

48,068

Operating income

 

3,879

 

9,105

1,580

 

12,876

^

27,440

Net income

 

14,965

 

9,105

 

1,580

 

(1,443)

^

24,207


^

- See table below for additional details.

Other Non-GAAP Adjustments (Q4 2024)

(in thousands)
(unaudited)

Three months ended December 31, 2024

    

Asset impairment

$

28,131

Changes in contingent consideration

(16,466)

Other

1,211

Subtotal

12,876

Non-cash interest expense

 

322

Tax benefits associated with asset impairments

(12,239)

Non-GAAP tax adjustment *

 

(2,402)

Total Other

$

(1,443)


*

- The ‘with or without’ method is utilized to determine the income tax effect of all Non-GAAP adjustments.

Net Income per Common Share (Q4 2024)

(in thousands, except per share amounts)
(unaudited)

Three months ended December 31, 2024

GAAP

Non-GAAP

Numerator:

Net income

    

$

14,965

    

$

24,207

Interest expense associated with 2025 and 2027 Convertible Senior Notes

 

513

 

 

466

Net income available to common shareholders

$

15,478

$

24,673

Denominator:

Basic weighted average shares outstanding

56,536

56,536

Effect of potentially dilutive share-based awards

1,070

1,070

Dilutive effect of 2025 Convertible Senior Notes

1,104

1,104

Dilutive effect of 2027 Convertible Senior Notes (1)

 

1,789

 

 

1,354

Diluted weighted average shares outstanding

60,499

60,064

Net income per common share:

Basic

$

0.26

$

0.43

Diluted

$

0.26

$

0.41


(1)  -  The non-GAAP incremental dilutive shares includes the impact of the Company’s capped call transaction issued concurrently with our 2027 Notes, and as such, an effective conversion price of $18.46 is used when determining incremental shares to add to the dilutive share count. The GAAP incremental dilutive shares does not include the impact of the Company’s capped call transaction, and as such, an effective conversion price of $13.98 is used when determining incremental shares to add to the dilutive share count.

5


Reconciliation of GAAP to Non-GAAP Financial Data (Q4 2023)

(in thousands)
(unaudited)

Non-GAAP Adjustments

 

Share-based

Three months ended December 31, 2023

    

GAAP

    

Compensation

    

Amortization

    

Other

    

Non-GAAP

Net sales

$

173,924

$

173,924

Gross profit

 

78,655

 

334

 

 

78,989

Gross margin

 

45.2

%  

45.4

%

Operating expenses

 

54,472

 

(5,845)

(2,123)

363

46,867

Operating income

 

24,183

 

6,179

2,123

 

(363)

^

32,122

Net income

 

21,637

 

6,179

 

2,123

 

(116)

^

29,823


^

- See table below for additional details.

Other Non-GAAP Adjustments (Q4 2023)

(in thousands)
(unaudited)

Three months ended December 31, 2023

Changes in contingent consideration

$

(465)

Other

102

Subtotal

(363)

Non-cash interest expense

 

294

Non-GAAP tax adjustment *

 

(47)

Total Other

$

(116)


*

- The ‘with or without’ method is utilized to determine the income tax effect of all Non-GAAP adjustments.

Net Income per Common Share (Q4 2023)

(in thousands, except per share amounts)
(unaudited)

Three months ended December 31, 2023

GAAP

Non-GAAP

Numerator:

Net income

    

$

21,637

    

$

29,823

Interest expense associated with 2025 and 2027 Convertible Senior Notes

 

511

 

 

466

Net income available to common shareholders

$

22,148

$

30,289

Denominator:

Basic weighted average shares outstanding

55,537

55,537

Effect of potentially dilutive share-based awards

1,391

1,391

Dilutive effect of 2025 Convertible Senior Notes

1,104

1,104

Dilutive effect of 2027 Convertible Senior Notes (1)

 

1,789

 

 

1,355

Diluted weighted average shares outstanding

59,821

59,387

Net income per common share:

Basic

$

0.39

$

0.54

Diluted

$

0.37

$

0.51


(1)- The non-GAAP incremental dilutive shares includes the impact of the Company’s capped call transaction issued concurrently with our 2027 Notes, and as such, an effective conversion price of $18.46 is used when determining incremental shares to add to the dilutive share count. The GAAP incremental dilutive shares does not include the impact of the Company’s capped call transaction, and as such, an effective conversion price of $13.98 is used when determining incremental shares to add to the dilutive share count.

6


Reconciliation of GAAP Net Income to Non-GAAP Operating Income (Q4 2024 and 2023)

(in thousands)
(unaudited)

    

Three months ended

    

Three months ended

December 31, 2024

December 31, 2023

GAAP Net income

$

14,965

$

21,637

Share-based compensation

 

9,105

 

6,179

Amortization

 

1,580

 

2,123

Asset impairment

 

28,131

 

Changes in contingent consideration

 

(16,466)

 

(465)

Transition expenses related to San Jose expansion project

57

Acquisition related

 

 

45

Interest (income) expense, net

 

(476)

 

Other

1,211

Income tax expense (benefit)

 

(10,610)

 

2,546

Non-GAAP Operating income

$

27,440

$

32,122

Reconciliation of GAAP to Non-GAAP Financial Data (FY 2024)

(in thousands)
(unaudited)

Non-GAAP Adjustments

 

Share-based

For the year ended December 31, 2024

    

GAAP

    

Compensation

    

Amortization

    

Other

    

Non-GAAP

Net sales

$

717,301

$

717,301

Gross profit

 

304,005

 

6,263

 

162

 

310,430

Gross margin

 

42.4

%  

43.3

%

Operating expenses

 

237,024

 

(29,616)

(6,983)

(6,067)

194,358

Operating income

 

66,981

 

35,879

6,983

 

6,229

^

116,072

Net income (loss)

 

73,714

 

35,879

 

6,983

 

(12,233)

^

104,343


^

- See table below for additional details.

Other Non-GAAP Adjustments (FY 2024)

(in thousands)
(unaudited)

For the year ended December 31, 2024

    

Asset impairment

$

28,131

Changes in contingent consideration

(21,242)

Sale of productive assets

 

(2,033)

Other

1,373

Subtotal

6,229

Non-cash interest expense

 

1,257

Tax benefits associated with asset impairments

(12,239)

Non-GAAP tax adjustment *

 

(7,480)

Total Other

$

(12,233)


*

- The ‘with or without’ method is utilized to determine the income tax effect of all Non-GAAP adjustments.

7


Net Income per Common Share (FY 2024)

(in thousands, except per share amounts)
(unaudited)

Year ended December 31, 2024

GAAP

Non-GAAP

Numerator:

Net income

    

$

73,714

    

$

104,343

Interest expense associated with convertible notes

 

2,054

 

 

1,865

Net income available to common shareholders

$

75,768

$

106,208

Denominator:

Basic weighted average shares outstanding

56,426

56,426

Effect of potentially dilutive share-based awards

1,010

1,010

Dilutive effect of 2025 Convertible Senior Notes

1,104

1,104

Dilutive effect of 2027 Convertible Senior Notes (1)

 

1,788

 

 

1,354

Dilutive effect of 2029 Convertible Senior Notes

1,268

1,268

Diluted weighted average shares outstanding

61,596

61,162

Net income per common share:

Basic

$

1.31

$

1.85

Diluted

$

1.23

$

1.74


(1)  -  The non-GAAP incremental dilutive shares includes the impact of the Company’s capped call transaction issued concurrently with our 2027 Notes, and as such, an effective conversion price of $18.46 is used when determining incremental shares to add to the dilutive share count. The GAAP incremental dilutive shares does not include the impact of the Company’s capped call transaction, and as such, an effective conversion price of $13.98 is used when determining incremental shares to add to the dilutive share count.

Reconciliation of GAAP to Non-GAAP Financial Data (FY 2023)

(in thousands)
(unaudited)

Non-GAAP Adjustments

 

Share-based

For the year ended December 31, 2023

    

GAAP

    

Compensation

    

Amortization

    

Other

    

Non-GAAP

Net sales

$

666,435

$

666,435

Gross profit

 

285,059

 

4,913

 

232

 

290,204

Gross margin

 

42.8

%  

43.5

%

Operating expenses

 

215,119

 

(23,645)

(8,481)

(2,363)

180,630

Operating income

 

69,940

 

28,558

8,481

 

2,595

^

109,574

Net income (loss)

 

(30,368)

 

28,558

 

8,481

 

91,668

^

98,339


^

- See table below for additional details.

8


Other Non-GAAP Adjustments (FY 2023)

(in thousands)
(unaudited)

For the year ended December 31, 2023

Acquisition related

$

1,056

Changes in contingent consideration

701

Transition expenses related to San Jose expansion project

838

Subtotal

2,595

Non-cash interest expense

1,118

Other (income) expense, net

97,091

Non-GAAP tax adjustment *

 

(9,136)

Total Other

$

91,668


*

- The ‘with or without’ method is utilized to determine the income tax effect of all Non-GAAP adjustments.

Net Income per Common Share (FY 2023)

(in thousands, except per share amounts)
(unaudited)

Year ended December 31, 2023

GAAP

Non-GAAP

Numerator:

Net income (loss)

    

$

(30,368)

    

$

98,339

Interest expense associated with convertible notes

 

 

 

4,768

Net income (loss) available to common shareholders

$

(30,368)

$

103,107

Denominator:

Basic weighted average shares outstanding

53,769

53,769

Effect of potentially dilutive share-based awards

850

Dilutive effect of 2023 Convertible Senior Notes

21

Dilutive effect of 2025 Convertible Senior Notes

2,786

Dilutive effect of 2027 Convertible Senior Notes (1)

 

 

 

3,417

Diluted weighted average shares outstanding

53,769

60,843

Net income per common share:

Basic

$

(0.56)

$

1.83

Diluted

$

(0.56)

$

1.69


(1)  -  The non-GAAP incremental dilutive shares includes the impact of the Company’s capped call transaction issued concurrently with our 2027 Notes, and as such, an effective conversion price of $18.46 is used when determining incremental shares to add to the dilutive share count. The GAAP incremental dilutive shares does not include the impact of the Company’s capped call transaction, and as such, an effective conversion price of $13.98 is used when determining incremental shares to add to the dilutive share count.

9


Reconciliation of GAAP Net Income to Non-GAAP Operating Income (FY 2024 and 2023)

(in thousands)
(unaudited)

    

Year ended

    

Year ended

December 31, 2024

December 31, 2023

GAAP Net income (loss)

$

73,714

$

(30,368)

Share-based compensation

 

35,879

 

28,558

Amortization

 

6,983

 

8,481

Asset impairment

28,131

Acquisition related

1,056

Changes in contingent consideration

 

(21,242)

 

701

Transition expenses related to San Jose expansion project

 

 

838

Sales of productive assets

 

(2,033)

 

Interest (income) expense, net

 

(1,853)

 

1,187

Other

1,373

97,091

Income tax expense (benefit)

 

(4,880)

 

2,030

Non-GAAP Operating income (loss)

$

116,072

$

109,574

Reconciliation of GAAP to Non-GAAP Financial Data (Q1 2025)

(in millions, except per share amounts)

(unaudited)

Non-GAAP Adjustments

 

Guidance for the three months ending

Share-based

 

March 31, 2025

GAAP

Compensation

Amortization

   Other    

Non-GAAP

 

Net sales

    

$

155

    

-

    

$

175

    

    

    

    

$

155

    

-

    

$

175

Gross profit

 

63

 

-

 

72

 

2

 

 

 

65

 

-

 

74

Gross margin

 

41%

-

 

41%

 

 

 

42%

-

 

42%

Operating expenses

56

 

-

 

58

(8)

(1)

47

 

-

 

49

Operating income

7

-

14

10

1

18

-

25

Net income

$

7

 

-

$

13

 

10

 

1

(2)

$

16

 

-

$

22

Income per diluted common share

$

0.11

 

-

$

0.22

 

  

 

  

 

  

$

0.26

 

-

$

0.36

10


Income per Diluted Common Share (Q1 2025)

(in millions, except per share amounts)
(unaudited)

Guidance for the three months ending March 31, 2025

GAAP

Non-GAAP

Numerator:

Net income available to common shareholders

    

$

7

    

-

    

$

13

    

$

16

    

-

    

$

22

Denominator:

Basic weighted average shares outstanding

58

58

58

58

Effect of potentially dilutive share-based awards

1

 

1

1

 

1

Dilutive effect of 2027 Convertible Senior Notes (1)

 

2

 

1

 

1

Diluted weighted average shares outstanding

59

61

60

60

Net income per common share:

Income per diluted common share

$

0.11

-

$

0.22

$

0.26

-

$

0.36


(1)    - The non-GAAP incremental dilutive shares includes the impact of the Company’s capped call transaction issued concurrently with our 2027 Notes, and as such, an effective conversion price of $18.46 is used when determining incremental shares to add to the dilutive share count. The GAAP incremental dilutive shares does not include the impact of the Company’s capped call transaction, and as such, an effective conversion price of $13.98 is used when determining incremental shares to add to the dilutive share count.

Reconciliation of GAAP Net Income to Non-GAAP Operating Income (Q1 2025)

(in millions)
(unaudited)

Guidance for the three months ending March 31, 2025

    

    

    

GAAP Net income

$

7

 

-

$

13

Share-based compensation

 

10

 

-

 

10

Amortization

 

1

 

-

 

1

Income tax expense

-

1

Non-GAAP Operating income

$

18

 

-

$

25

Note: Amounts may not calculate precisely due to rounding.

11